Literature DB >> 2154521

A novel technique to link either proteins or peptides to gammaglobulin to construct tolerogens.

H Borel1, Y Borel.   

Abstract

In order to extend the concept of constructing tolerogens (i.e., compounds which induce immunologic tolerance), we developed a novel method to covalently link either protein or peptide to isologous gammaglobulin. We used disuccinimidyl suberate (DSS) for preparing protein conjugates in solution in a novel use of this reagent. We tested the efficacy of this method in two different experimental models: in the first, we found that administration of pigeon cytochrome C conjugated to mouse IgG in vivo induces T cell unresponsiveness in vitro. In the second, we induced unresponsiveness to factor VIII light chain both in newborn and, more importantly, in adult mice already immune to factor VIII. We hope that this simple method will provide a powerful tool to construct tolerogens useful in the specific treatment of either allergic or autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154521     DOI: 10.1016/0022-1759(90)90146-m

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Epitope-specific tolerance induction with an engineered immunoglobulin.

Authors:  E T Zambidis; D W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

2.  Induction of tolerance by administration of hapten-immunoglobulin conjugates is associated with decreased IL-2 and IL-4 production.

Authors:  V Dumas; W Ptak; M Demarchez; J H Saurat; Y Borel; C Hauser
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

3.  Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis.

Authors:  A Lobell; R Weissert; M K Storch; C Svanholm; K L de Graaf; H Lassmann; R Andersson; T Olsson; H Wigzell
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

Review 4.  Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.

Authors:  Maricel G Miguelino; Jerry S Powell
Journal:  Patient Prefer Adherence       Date:  2014-08-08       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.